Home › Funds › Brighthouse › T. Rowe Price Mid Cap Growth Portfolio
Fund family: Brighthouse · Filed by Brighthouse Funds Trust I (CIK 1126087) · SEC series S000011103
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,161 with, 22 against, 0 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 8 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Brighthouse’s manager page (247,741 ballot items across 83 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Brighthouse | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 93.4% | 1,118 | 76.3% | 204,500 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 12.8% | 1,182 |
Each ballot item this fund voted is set against the votes of the other Brighthouse funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Brighthouse funds on 65 items (6.8% of the 961 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Brighthouse funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Microchip Technology Incorporated | 2025-08-19 | Proposal to approve, on an advisory (non-binding) basis, the compensation of our named executives. | For | AGAINST or ABSTAIN — 8 of 8 Brighthouse funds | For | Not approved, 45.6% support |
| Molina Healthcare, Inc. | 2026-05-06 | To consider and approve an amendment to the Company's 2025 Equity Incentive Plan to increase the number of shares available for issuance under such plan. | For | AGAINST or ABSTAIN — 7 of 7 Brighthouse funds | For | Passed (calculated), 73.5% support |
| Natera, Inc. | 2026-06-11 | To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this noti | Withhold | FOR — 4 of 4 Brighthouse funds | Against | Passed (calculated), 98.3% support |
| Insulet Corporation | 2026-05-20 | Election of Directors: Luciana Borio | Withhold | FOR — 4 of 4 Brighthouse funds | Against | Passed (calculated), 93.5% support |
| Insulet Corporation | 2026-05-20 | Election of Directors: Michael R. Minogue | Withhold | FOR — 4 of 4 Brighthouse funds | Against | Passed (calculated), 91.1% support |
| Insulet Corporation | 2026-05-20 | Election of Directors: Timothy C. Stonesifer | Withhold | FOR — 4 of 4 Brighthouse funds | Against | Passed (calculated), 95.4% support |
| Dutch Bros Inc. | 2026-05-13 | Election of Directors: Todd Penegor | Against | FOR — 4 of 4 Brighthouse funds | Against | Elected, 91.7% support |
| Veeva Systems Inc. | 2026-06-17 | To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Gordon Ritter | For | ABSTAIN or AGAINST — 7 of 9 Brighthouse funds | For | Elected, 73.6% support |
| Veeva Systems Inc. | 2026-06-17 | To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Mark Carges | For | ABSTAIN or AGAINST — 7 of 9 Brighthouse funds | For | Elected, 80.0% support |
| Veeva Systems Inc. | 2026-06-17 | To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Matthew J. Wallach | For | AGAINST — 3 of 3 Brighthouse funds | For | Elected, 63.7% support |
| MongoDB, Inc. | 2026-06-30 | Election of three Class III directors, each to serve until our Annual Meeting of Stockholders in 2029: Dwight Merriman | For | WITHHOLD — 3 of 3 Brighthouse funds | For | Elected, 80.4% support |
| APi Group Corporation | 2026-05-15 | To elect nine directors for a one-year term expiring at the 2027 Annual Meeting of Shareholders: Cyrus D. Walker | For | AGAINST — 5 of 6 Brighthouse funds | For | Passed (calculated), 81.1% support |
| Assurant, Inc. | 2026-05-21 | Shareholder Stockholder proposal regarding action by written consent. | Against | FOR — 5 of 6 Brighthouse funds | For | Not approved, 29.2% support |
| Manhattan Associates, Inc. | 2026-05-14 | Election of Directors: Eddie Capel | Against | FOR — 3 of 3 Brighthouse funds | Against | Elected, 85.6% support |
| Manhattan Associates, Inc. | 2026-05-14 | Election of Directors: Linda T. Hollembaek | Against | FOR — 3 of 3 Brighthouse funds | Against | Elected, 75.4% support |
| The New York Times Company | 2026-04-22 | Election of Directors: Class A Nominees: Brian P. McAndrews | Withhold | FOR — 3 of 3 Brighthouse funds | Against | Passed (calculated), 81.7% support |
| The New York Times Company | 2026-04-22 | Election of Directors: Class A Nominees: John W. Rogers, Jr. | Withhold | FOR — 3 of 3 Brighthouse funds | Against | Passed (calculated), 91.2% support |
| Planet Fitness, Inc. | 2026-05-05 | Election of the four director nominees named in the proxy statement as set forth below: Stephen Spinelli, Jr. | For | WITHHOLD — 3 of 3 Brighthouse funds | For | Elected, 73.5% support |
| Viking Holdings Ltd | 2026-05-13 | Elect Director Torstein Hagen | For | AGAINST — 3 of 3 Brighthouse funds | For | — |
| Viking Holdings Ltd | 2026-05-13 | Elect Torstein Hagen as Board Chairman | For | AGAINST — 3 of 3 Brighthouse funds | For | — |
| Yum! Brands, Inc. | 2026-05-14 | Shareholder Shareholder Proposal to Reduce the Percentage of Shares Required to Call a Special Meeting. | Against | FOR — 8 of 13 Brighthouse funds | For | Not approved, 37.7% support |
| Cboe Global Markets, Inc. | 2026-05-14 | Shareholder Stockholder proposal regarding shareholder right to act by written consent. | Against | FOR — 6 of 9 Brighthouse funds | For | — |
| Biogen Inc. | 2026-06-09 | Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified: Maria C. Freire | For | ABSTAIN or AGAINST — 7 of 11 Brighthouse funds | For | Passed (calculated), 84.6% support |
| Biogen Inc. | 2026-06-09 | Say on Pay - To hold an advisory vote on executive compensation. | For | ABSTAIN or AGAINST — 7 of 11 Brighthouse funds | For | Approved, 93.9% support |
| Biogen Inc. | 2026-06-09 | To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026. | For | ABSTAIN or AGAINST — 7 of 11 Brighthouse funds | For | Approved, 94.9% support |
| Company | Meeting | Item | This fund | Most Brighthouse funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Natera, Inc. | 2026-06-11 | To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated. | For | ABSTAIN or AGAINST — 9 of 16 Brighthouse funds | For | Passed (calculated), 78.1% support |
| StandardAero, Inc. | 2026-06-25 | 3 wordings Election of Class II Directors to serve until the 2029 Annual Meeting of Stockholder, and until their respective successors shall have been duly elected and qualified: Douglas V. Brandely | For | WITHHOLD — 5 of 8 Brighthouse funds | For | Elected, 85.0% support |
| Cytokinetics, Incorporated | 2026-05-27 | Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D. | Withhold | FOR — 5 of 8 Brighthouse funds | Against | Passed (calculated), 79.2% support |
| CG Oncology, Inc. | 2026-06-04 | To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Victor Tong, Jr. | For | WITHHOLD — 5 of 8 Brighthouse funds | For | Elected, 92.3% support |
| Hologic, Inc. | 2026-02-05 | A proposal to approve any adjournment of the special meeting for the purpose of soliciting additional proxies if there are insufficient votes at the special meeting to adopt the merger agreement. | Against | FOR — 6 of 10 Brighthouse funds | Against | — |
| Atlassian Corporation | 2025-12-02 | Election of Directors: Michael Cannon-Brookes | For | ABSTAIN or AGAINST — 3 of 4 Brighthouse funds | For | Passed (calculated), 96.9% support |
| Atlassian Corporation | 2025-12-02 | Election of Directors: Scott Farquhar | For | ABSTAIN or AGAINST — 3 of 4 Brighthouse funds | For | Passed (calculated), 96.9% support |
| Markel Group Inc. | 2026-05-20 | Shareholder Shareholder proposal to give shareholders an ability to call for a special shareholder meeting. | Against | FOR — 3 of 4 Brighthouse funds | For | Failed (calculated), 37.3% support |
| Kymera Therapeutics, Inc. | 2026-06-24 | To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil. | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Passed (calculated), 93.0% support |
| Kymera Therapeutics, Inc. | 2026-06-24 | To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFA | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Passed (calculated), 93.6% support |
| Kymera Therapeutics, Inc. | 2026-06-24 | To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Maraganore, Ph.D. | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Passed (calculated), 93.7% support |
| Kymera Therapeutics, Inc. | 2026-06-24 | To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Nello Mainolfi, Ph.D. | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Passed (calculated), 94.9% support |
| Vaxcyte, Inc. | 2026-06-15 | 2 wordings Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D. | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Passed (calculated), 87.5% support |
| Aurora Innovation, Inc. | 2026-05-21 | Election of Directors: Gloria Boyland | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Elected, 97.3% support |
| Nuvalent, Inc. | 2026-06-16 | Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D. | For | WITHHOLD — 3 of 4 Brighthouse funds | For | Elected, 81.5% support |
| Biogen Inc. | 2026-06-09 | 8 wordings Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified: William A. Hawkins | For | ABSTAIN — 6 of 11 Brighthouse funds | For | Passed (calculated), 83.8% support |
| Cheniere Energy, Inc. | 2026-05-14 | Election of Directors: Patricia K. Collawn | For | ABSTAIN or AGAINST — 5 of 9 Brighthouse funds | For | Elected, 94.2% support |
| Veeva Systems Inc. | 2026-06-17 | To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Mary Lynne Hedley | For | ABSTAIN or AGAINST — 5 of 9 Brighthouse funds | For | Elected, 86.6% support |
| Alnylam Pharmaceuticals, Inc. | 2026-05-20 | To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026. | For | ABSTAIN or AGAINST — 5 of 9 Brighthouse funds | For | Approved, 95.3% support |
| ITT Inc. | 2026-05-21 | Approval of a non-binding advisory vote on executive compensation | For | ABSTAIN — 4 of 7 Brighthouse funds | For | Approved, 96.8% support |
| ITT Inc. | 2026-05-21 | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the 2026 fiscal year | For | ABSTAIN — 4 of 7 Brighthouse funds | For | Approved, 97.3% support |
| Zscaler, Inc. | 2026-01-12 | To approve on a non-binding, advisory basis, the frequency of future stockholder advisory votes on the compensation of our named executive officers. | For | ABSTAIN — 3 of 5 Brighthouse funds | For | — |
| Ball Corporation | 2026-04-29 | Election of Directors: Todd A. Penegor | Against | FOR — 3 of 5 Brighthouse funds | Against | Passed (calculated), 60.3% support |
| Service Corporation International | 2026-05-06 | To approve the 2026 Equity Incentive Plan. | For | AGAINST — 3 of 5 Brighthouse funds | For | Approved, 78.1% support |
| Avantor, Inc. | 2026-05-07 | Election of Directors: Dame Louise Makin | For | ABSTAIN or AGAINST — 3 of 5 Brighthouse funds | For | Passed (calculated), 95.7% support |
| Avantor, Inc. | 2026-05-07 | Election of Directors: Gregory Lucier | For | ABSTAIN or AGAINST — 3 of 5 Brighthouse funds | For | Passed (calculated), 97.6% support |
| Avantor, Inc. | 2026-05-07 | Election of Directors: Gregory Summe | For | ABSTAIN or AGAINST — 3 of 5 Brighthouse funds | For | Passed (calculated), 87.0% support |
| Avantor, Inc. | 2026-05-07 | Election of Directors: Joseph Massaro | For | ABSTAIN or AGAINST — 3 of 5 Brighthouse funds | For | Passed (calculated), 95.3% support |
| Wyndham Hotels & Resorts, Inc. | 2026-05-14 | Shareholder To vote on a stockholder proposal, if properly presented at the meeting, regarding stockholder ability to act by written consent. | Against | FOR — 3 of 5 Brighthouse funds | For | Passed (calculated), 62.9% support |
| Revolution Medicines, Inc. | 2026-06-18 | To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy | For | WITHHOLD — 2 of 3 Brighthouse funds | For | Passed (calculated), 79.1% support |
| DraftKings Inc. | 2026-05-12 | To conduct a non-binding advisory vote on executive compensation. | For | ABSTAIN or AGAINST — 2 of 3 Brighthouse funds | For | Passed (calculated), 97.2% support |
| Ralliant Corporation | 2026-06-05 | Advisory vote on the frequency of future advisory votes to approve Ralliant's named executive officer compensation. | For | ABSTAIN — 2 of 3 Brighthouse funds | For | — |
| Ionis Pharmaceuticals, Inc. | 2026-06-04 | Election of Directors: Spencer R. Berthelsen | Against | FOR — 2 of 3 Brighthouse funds | Against | Passed (calculated), 85.2% support |
| CRISPR Therapeutics AG | 2026-06-04 | Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan. | For | AGAINST — 2 of 3 Brighthouse funds | For | Approved, 88.1% support |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders. | For | AGAINST — 2 of 3 Brighthouse funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders. | For | AGAINST — 2 of 3 Brighthouse funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027. | For | AGAINST — 2 of 3 Brighthouse funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026. | For | AGAINST — 2 of 3 Brighthouse funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Non-binding advisory vote on the 2025 Compensation Report. | For | AGAINST — 2 of 3 Brighthouse funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements. | For | AGAINST — 2 of 3 Brighthouse funds | For | Approved, 69.4% support |
Download all 65 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 92.4% of this fund’s 1,183 such votes could be given a sector; the other 90 (7.6%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Consumer Discretionary | 338 | 9 | 2.7% |
| Health Care | 219 | 1 | 0.5% |
| Industrials | 176 | 1 | 0.6% |
| Technology | 171 | 2 | 1.2% |
| Finance | 129 | 6 | 4.7% |
| Miscellaneous | 26 | 0 | 0.0% |
| Utilities | 21 | 1 | 4.8% |
| Energy | 13 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 843 | 0 |
| Audit-related | 110 | 0 |
| Say-on-Pay | 108 | 0 |
| Corporate Governance | 57 | 19 |
| Compensation | 36 | 0 |
| Capital Structure | 18 | 0 |
| Shareholder Rights and Defenses | 8 | 1 |
| Extraordinary Transactions | 3 | 0 |
| Environment or Climate | 1 | 1 |
| Other Social Issues | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Hilton Worldwide Holdings Inc. | May 14, 2026 | $35M | 13 | 0 |
| Agilent Technologies, Inc. | March 18, 2026 | $30M | 7 | 0 |
| Mettler-Toledo International Inc. | May 7, 2026 | $26M | 11 | 0 |
| PTC Inc. | February 11, 2026 | $26M | 10 | 0 |
| Lattice Semiconductor Corporation | May 1, 2026 | $25M | 10 | 0 |
| Assurant, Inc. | May 21, 2026 | $24M | 14 | 1 |
| Veeva Systems Inc. | June 17, 2026 | $23M | 10 | 0 |
| Yum! Brands, Inc. | May 14, 2026 | $21M | 14 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 21, 2026 | Assurant, Inc. | Stockholder proposal regarding action by written consent. Shareholder proposal | Against | For |
| May 14, 2026 | Yum! Brands, Inc. | Shareholder Proposal to Reduce the Percentage of Shares Required to Call a Special Meeting. Shareholder proposal | Against | For |
| March 19, 2026 | Keysight Technologies, Inc. | Consider, on a non-binding advisory basis, a Stockholder Proposal: Shareholder Ability to Call for a Special Shareholder Meeting Shareholder proposal | For | Against |
| June 16, 2026 | Dollar Tree, Inc. | Shareholder proposal requesting a shareholder right to act by written consent. Shareholder proposal | Against | For |
| September 3, 2025 | Casey's General Stores, Inc. | Shareholder proposal regarding Scope 3 greenhouse gas reduction targets. Shareholder proposal | Against | For |
| May 4, 2026 | West Pharmaceutical Services, Inc. | Shareholder proposal regarding an independent Board Chair policy. Shareholder proposal | For | Against |
| May 14, 2026 | Cboe Global Markets, Inc. | Stockholder proposal regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| April 21, 2026 | Domino's Pizza, Inc. | Shareholder proposal regarding departure of directors who fail to obtain a majority vote. Shareholder proposal | Against | For |
| April 21, 2026 | Domino's Pizza, Inc. | Shareholder proposal regarding an independent board chair requirement. Shareholder proposal | For | Against |
| April 30, 2026 | Avery Dennison Corporation | Vote on stockholder proposal for an independent Board Chairman, if properly presented during the meeting. Shareholder proposal | For | Against |
| January 12, 2026 | Zscaler, Inc. | To vote on a non-binding stockholder proposal requesting the declassification of our board of directors. Shareholder proposal | For | Against |
| May 20, 2026 | Markel Group Inc. | Shareholder proposal for a report on the Company's strategies and action plans to mitigate material environmental risks. Shareholder proposal | Against | For |
1,185 ballot items at 111 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, T. Rowe Price Mid Cap Growth Portfolio voted at 111 shareholder meetings of 109 companies, on 1,185 ballot items in all. Where management made a recommendation, the fund followed it on 98.1% of the items and voted against it 22 times. Its most frequent area of disagreement was corporate governance (19 of its votes against management). It voted on 20 shareholder proposals. It voted FOR the board's own proposals more often than Brighthouse's funds as a whole (93.4% against 76.3%). It voted differently from most Brighthouse funds on 65 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Brighthouse’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.